Cytokinetics, Amgen: Heart Failure Drug Misses Primary Endpoint NASDAQ Cytokinetics Inc. ( CYTK ) and Amgen Inc. ( AMGN ) said results from a mid-stage trial for their experimental drug for acute heart failure failed to meet its primary endpoint. Shares of Cytokinetics were down 17% to $8.66 in premarket trade. Amgen ... |
